+ -Text Size

Peer Review Committee for Cancer Drug Discovery (CDD)

Areas reviewed: Chemical studies dealing with the modification or development of drugs. Preclinical studies involving toxicity and effectiveness, and the development of drug delivery systems. Pharmacological studies, and studies involving nuclear magnetic resonance and crystallography, on the mechanisms of drug action, and the application of this information to drug design. Studies on the isolation, testing, and synthesis of natural therapeutic agents.

Brent Rupnow, PhD, Chair 
Bristol-Meyers Squibb Company, Princeton, NJ

James L. Leighton, PhD, Vice Chair
Columbia University, New York, NY

Robert Antenucci, Stakeholder
Warren, OH

Demetrios T. Braddock, MD, PhD
Yale University, New Haven, CT 

Georgia Chen, PhD
Emory University, Winship Cancer Center, Atlanta, GA

Jing Chen, PhD
Emory University, Atlanta, GA

Dashyant Dhanak, PhD
GlaxoSmithKline, Collegeville, PA

Robert A. Fecik, PhD
University of Minnesota, Minneapolis, MN

Sandaruwan Geeganage, PhD
Eli Lilly and Company, Indianapolis, IN 

William G. Hawkins, MD
Washington University, St. Louis, MO  

Christine A. Hrycyna, PhD
Purdue University, West Lafayette, IN

Joseph Kissil, PhD
The Scripps Research Institute, Jupiter, FL

Joerg Lahann, PhD
University of Michigan, Ann Arbor, MI

George A. O'Doherty, PhD
Northeastern University, Boston, MA

Robert Z. Orlowski, MD, PhD
University of Texas, MD Anderson Cancer Center, Houston, TX

Keykavous Parang, PharmD, PhD
University of Rhode Island, Kingston, RI

Aliasger K. Salem, PhD
University of Iowa, Iowa City, IA

Rich Truett, Stakeholder
Eugene, OR

Coran M. Watanabe, PhD
Texas A&M University, College Station, TX